Wealthfront Advisers LLC Has $3.94 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Wealthfront Advisers LLC lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 38.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,084 shares of the biopharmaceutical company’s stock after buying an additional 3,363 shares during the quarter. Wealthfront Advisers LLC’s holdings in Alnylam Pharmaceuticals were worth $3,940,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Bessemer Group Inc. grew its position in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 69 shares in the last quarter. Crossmark Global Holdings Inc. bought a new stake in Alnylam Pharmaceuticals in the first quarter worth $275,000. Strs Ohio bought a new position in Alnylam Pharmaceuticals during the first quarter valued at about $7,781,000. GAMMA Investing LLC lifted its position in shares of Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 77 shares during the last quarter. Finally, Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $243,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $475.91 on Wednesday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The stock has a market capitalization of $62.38 billion, a PE ratio of -192.68 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The stock’s fifty day moving average is $460.05 and its 200-day moving average is $365.19.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same period in the prior year, the company posted ($0.13) EPS. The company’s revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ALNY shares. Chardan Capital lifted their price target on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a “buy” rating in a report on Monday, October 6th. Jefferies Financial Group boosted their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a research report on Monday, July 7th. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Finally, HC Wainwright reissued a “buy” rating and set a $570.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 10th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $466.92.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares in the company, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,405 shares of the business’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $635,130.25. Following the completion of the transaction, the executive vice president directly owned 27,438 shares of the company’s stock, valued at $12,403,347.90. This trade represents a 4.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 over the last ninety days. Company insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.